Boston Scientific Corp.’s (NYSE:BSX) third-generation coronary stent, the Taxus Element, is set to hit the market in Europe next month.
The Natick, Mass.-based medical device giant said the latest version of its paclitaxel-eluting stent, made of a platinum-chromium alloy, won CE Mark approval in the European Union. The approval includes an indication for treatment of diabetics, according to a press release.